

Title (en)
HETEROARYLCARBOXAMIDE COMPOUNDS ACTIVE AGAINST PROTEIN TYROSINE KINASE RELATED DISORDERS

Title (de)
HETEROARYLCARBOXAMID-VERBINDUNGEN DIE GEGEN DURCH PROTEIN-TYROSIN-KINASE VERURSACHTE KRANKHEITEN WIRKSAM SIND

Title (fr)
COMPOSES D'HETEROARYLCARBOXAMIDE ACTIFS CONTRE LES ETATS PATHOLOGIQUES LIES AUX PROTEINE TYROSINE KINASES

Publication
EP 1012150 A4 20020529 (EN)

Application
EP 98924794 A 19980518

Priority

- US 9810174 W 19980518
- US 4708497 P 19970519
- US 4694597 P 19970519
- US 5662397 P 19970820
- US 6159097 P 19971010

Abstract (en)
[origin: WO9852944A1] The present invention relates to novel heteroarylcarboxamides which modulate the activity of protein tyrosine kinases and are expected to be useful in the treatment of abnormal protein tyrosine kinase activity driven disorders, to methods for the treatment of inappropriate FGFR activity related disorders with the heteroarylcarboxamide, N-(4-trifluoromethyl-phenyl)-5-methylisoxazole-4-carboxamide, and to the treatment of solid tumor cancers, especially glioblastoma and astrocytoma, with a combination of a nitrosourea, preferably BCNU (carmustin) and N-(4-trifluoromethyl-phenyl)-5-methylisoxazole-4-carboxamide.

IPC 1-7
C07D 413/02; C07D 231/12; C07D 261/18; C07D 261/08; C07D 413/12; C07D 231/14; C07D 401/12; C07D 407/12; C07D 275/02; C07D 417/12; A61K 31/42; A61K 31/415; A61K 31/44; A61K 31/425

IPC 8 full level
C07D 231/12 (2006.01); **C07D 261/18** (2006.01); **C07D 277/32** (2006.01); **C07D 401/12** (2006.01); **C07D 413/12** (2006.01)

CPC (source: EP)
C07D 261/18 (2013.01); **C07D 277/32** (2013.01); **C07D 401/12** (2013.01); **C07D 413/12** (2013.01)

Citation (search report)

- [XY] EP 0769296 A1 19970423 - HOECHST AG [DE]
- [XY] WO 9633179 A1 19961024 - SUGEN INC [US], et al
- [DXY] WO 9519169 A2 19950720 - SUGEN INC [US], et al
- [XY] US 5476866 A 19951219 - KUO ELIZABETH A [GB], et al
- [DXY] WO 9117748 A1 19911128 - HOECHST AG [DE]
- [X] WO 9401408 A1 19940120 - GLAXO LAB SA [FR], et al
- [X] US 5342851 A 19940830 - SANFILIPPO PAULINE J [US], et al
- [X] WO 9711690 A2 19970403 - MICROCID PHARMACEUTICALS INC [US]
- [PY] WO 9740019 A1 19971030 - CELLTECH THERAPEUTICS LTD [GB], et al
- [E] WO 9828269 A1 19980702 - DU PONT MERCK PHARMA [US]
- [E] EP 0990645 A1 20000405 - NIPPON KAYAKU KK [JP]
- [E] WO 9857937 A2 19981223 - DU PONT MERCK PHARMA [US]
- [E] WO 9924404 A1 19990520 - AMGEN INC [US]
- [E] WO 9943657 A1 19990902 - HOFFMANN LA ROCHE [CH]
- [X] EP 0418667 A2 19910327 - BASF AG [DE]
- [X] EP 0073973 A1 19830316 - BASF AG [DE]
- [X] DATABASE WPI Week 9539, Derwent World Patents Index; AN 1995-299548, XP002192889
- [X] DATABASE CROSSFIRE BEILSTEIN [online] Beilstein Institut zur Förderung der Chemischen Wissenschaften, Frankfurt am Main, DE; XP002192888, Database accession no. 1576091 (BRN) & J. CHEM. SOC. C (1968), (5), 611-14
- See references of WO 9852944A1

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 9852944 A1 19981126; AR 015685 A1 20010516; AU 7687998 A 19981211; CA 2302438 A1 19981126; EP 1012150 A1 20000628; EP 1012150 A4 20020529

DOCDB simple family (application)
US 9810174 W 19980518; AR P980102308 A 19980519; AU 7687998 A 19980518; CA 2302438 A 19980518; EP 98924794 A 19980518